Atlas Trials

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Clinical trial NCT04513028 · RECRUITING

Trial details

NCT number
NCT04513028
Sponsor
Kelly McMasters
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Melanoma Stage IIIMelanoma Stage IV
Start date
2020-11-03
Primary completion
2026-07-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.